



Grant of Share Options

November 23, 2023
RNS Number : 3917U
Renalytix PLC
23 November 2023

Renalytix plc ("Renalytix" or the "Company")

Grant of Share Options

LONDON and SALT LAKE CITY - November 23, 2023 - [Renalytix plc](https://www.renalytix.com) (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that the Board have granted options over a total of 380,000 ordinary shares of 0.25 pence each in the capital of the Company (the "Share Options") to the following individuals:

Name	Position	Options granted
Christopher Mills	Non-Executive Chairman	95,000
Daniel Levangie	Non-Executive Director	95,000
Chirag Parikh	Non-Executive Director	95,000
Catherine Coste	Non-Executive Director	95,000

The Share Options, which have been issued in line with the Company's existing share option plan, have an exercise price of £0.245 per ordinary share, being the closing price of the shares on the 17 November 2023.

All the Share Options granted one twelfth of the Share Options vest 3 months from the date of grant with one twelfth vesting quarterly after that, subject to the individuals remaining employed by the Company as Non-Executive Directors.

The issue of the Share Options are deemed to be related party transactions pursuant to AIM Rule 13 of the AIM Rules for Companies. The Company's directors (excluding those who are being awarded the Share Options) consider, having consulted with the Nominated Adviser, Stifel Nicolaus Europe Limited, that the terms of the related party transactions are fair and reasonable insofar as the shareholders of the Company are concerned.

For further information, please contact:

Renalytix plc
James McCullough, CEO

www.renalytix.com
Via Walbrook PR

Stifel (Nominated Adviser, Joint Broker)

Tel: 020 7710 7600

Alex Price / Nicholas Moore / Nick Harland / Samira
Essebiyea

Investec Bank plc (Joint Broker)

Tel: 020 7597 4000

Gary Clarence / Shalin Bhamra

Walbrook PR Limited

Tel: 020 7933 8780 or renalytix@walbrookpr.com

Paul McManus / Alice Woodings

Mob: 07980 541 893 / 07584 391 303 / 07407 804 654

CapComm Partners

Peter DeNardo

Tel: 415-389-6400 or investors@renalytix.com

About Renalytix

About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.

1	Details of the person discharging managerial responsibilities / person closely associated					
a)	Name	Christopher Mills				
2	Reason for the notification					
a)	Position/status	Non-Executive Chairman				
b)	Initial notification /Amendment	Initial notification				
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	Renalytix plc				
b)	LEI	213800NTOH3FK3WER551				
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a)	Description of the financial instrument, type of instrument Identification code	Options over ordinary shares of 0.25 pence each in the Company GB00BYWL4Y04				
b)	Nature of the transaction	Grant of options over shares				
c)	Price(s) and volume(s)	<table border="1"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>£0.245</td> <td>95,000</td> </tr> </table>	Price(s)	Volume(s)	£0.245	95,000
Price(s)	Volume(s)					
£0.245	95,000					
d)	Aggregated information	 <div> - Aggregated volume - Price </div> <div> 95,000 £23,275 </div>				
e)	Date of the transaction	21 November 2023				

f)	Place of the transaction	Outside of trading venue - off market

1	Details of the person discharging managerial responsibilities / person closely associated					
a)	Name	Dan Levangie				
2	Reason for the notification					
a)	Position/status	Non-Executive Director				
b)	Initial notification /Amendment	Initial notification				
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	Renalytix plc				
b)	LEI	213800NTOH3FK3WER551				
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a)	Description of the financial instrument, type of instrument Identification code	Options over ordinary shares of 0.25 pence each in the Company GB00BYWL4Y04				
b)	Nature of the transaction	Grant of options over shares				
c)	Price(s) and volume(s)	<table border="1"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>£0.245</td> <td>95,000</td> </tr> </table>	Price(s)	Volume(s)	£0.245	95,000
Price(s)	Volume(s)					
£0.245	95,000					
d)	Aggregated information - Aggregated volume - Price	 95,000 £23,275				

e)	Date of the transaction	21 November 2023
f)	Place of the transaction	Outside of trading venue - off market

1	Details of the person discharging managerial responsibilities / person closely associated					
a)	Name	Chirag Parikh				
2	Reason for the notification					
a)	Position/status	Non-Executive Director				
b)	Initial notification /Amendment	Initial notification				
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	Renalytix plc				
b)	LEI	213800NTOH3FK3WER551				
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a)	Description of the financial instrument, type of instrument Identification code	Options over ordinary shares of 0.25 pence each in the Company GB00BYWL4Y04				
b)	Nature of the transaction	Grant of options over shares				
c)	Price(s) and volume(s)	<table border="1"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>£0.245</td> <td>95,000</td> </tr> </table>	Price(s)	Volume(s)	£0.245	95,000
Price(s)	Volume(s)					
£0.245	95,000					
d)	Aggregated information - Aggregated volume	 95,000				

	- Price	£23,275
e)	Date of the transaction	21 November 2023
f)	Place of the transaction	Outside of trading venue - off market

1	Details of the person discharging managerial responsibilities / person closely associated					
a)	Name	Catherine Coste				
2	Reason for the notification					
a)	Position/status	Non-Executive Director				
b)	Initial notification /Amendment	Initial notification				
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	Renalytix plc				
b)	LEI	213800NTOH3FK3WER551				
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a)	Description of the financial instrument, type of instrument Identification code	Options over ordinary shares of 0.25 pence each in the Company GB00BYWL4Y04				
b)	Nature of the transaction	Grant of options over shares				
c)	Price(s) and volume(s)	<table border="1"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>£0.245</td> <td>95,000</td> </tr> </table>	Price(s)	Volume(s)	£0.245	95,000
Price(s)	Volume(s)					
£0.245	95,000					
d)	Aggregated information					

	- Aggregated volume	95,000
	- Price	£23,275
e)	Date of the transaction	21 November 2023
f)	Place of the transaction	Outside of trading venue - off market

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHFLLLLXFLBFBE